口服替莫唑胺同步放射治疗脑转移瘤的疗效评价

Evaluation of the Efficacy of Temozolomide plus Concomitant Radiotherapy in the Patients with Brain Metastases

目的评价替莫唑胺化疗同步放射治疗脑转移瘤疗效及不良反应。方法 95例脑转移瘤患者随机分为治疗组和对照组,治疗组47例口服替莫唑胺化疗同步放疗;对照组48例单纯放疗。比较两组患者的临床疗效和不良反应情况。结果治疗组总缓解率为100%,对照组总缓解率为89.5%,差异有统计学意义(P<0.05);治疗组复发中位时间和中位生存时间均长于对照组,差异有统计学意义(P<0.05);两组不良反应情况比较差异无统计学意义(P>0.05),患者均能耐受。结论口服替莫唑胺化疗同步放疗治疗脑转移瘤安全、有效,可提高脑转移瘤控制率和延长中位生存期。

Objective To evaluate the efficacy and adverse reactions of temozolomide plus concomitant radiotherapy in the patients with brain metastases.Methods 95 patients with brain metastases were divided into the treatment group and the control group randomly.47 patients were treated by temozolomide plus concomitant radiotherapy in the treatment group.And 48 patients were treated by radiotherapy alone.The efficacy and the adverse reactions in the two groups were compared.Results The overall remission rates were 100% in the treatment group,89.5% in the control group,significant difference between these two groups（P0.05）.The median recurrent period and the median survival period in the treatment group were longer than the control group with significant difference（P0.05）.The adverse reactions between these two groups have no significant difference（P0.05）.All the patients can tolerate the treatment.Conclusion For brain metastases,temozolomide plus concomitant radiotherapy is safe and efficient,and can increase the metastasis control rate and prolong the median survival time.